In pharma, every year seems to bring forth even more change than the year before, but 2023 just might take the cake. Stakeholders have had to adjust to new developments in the healthcare ecosystem such as the Inflation Reduction Act, the rise of immunology biosimilars and insulin price changes impacting payer rebate economics, and the recent ruling that insurers can no longer implement copay accumulator adjustor programs, among many others.
Over the next few years, several more trends are poised to redefine how manufacturers, payers and providers interact. Manufacturers will need to stay abreast of the changing market access landscape—or risk falling behind.
To find out the four trends that will shape the future of market access, read the full article on Drug Channels. And for expert guidance and advice to help you weather the changes ahead, learn how MMIT and its sister company, The Dedham Group, can help.
